FDA announced it will issue a series of guidance documents this fall surrounding regenerative medicinal products that will define an efficient process for how these products should be evaluated for quality, safety and effectiveness. The agency also plans increased oversight and enforcement, and expects the new framework will clarify when such medicines are of sufficient complexity to fall under the agency’s current authority. The announcement follows two warning letters issued to “stem cell clinics” in Florida and California.
[/membership]
